Drug
Kbp 5074
Kbp 5074: highest development phase Phase 3, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| KBP-5074 NCT04968184 | Phase 3 | Chronic Kidney Diseases |
Latest
No recent events.
Follow Kbp 5074 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.